2015 ISHLT Annual Meeting and Scientific Sessions

Apr 15, 2015 ‐ Apr 18, 2015


Standard: $250.00

Sessions

PRE-MEETING SYMPOSIUM 01: INTERMACS 0: Treatment of the Patient in Shock -- Are All INTERMACs Profile I Patients the Same? Definition, Categorization and Outcomes with Shock

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY01a

There is substantial evidence showing that patients presenting with critical cardiogenic shock/INTERMACS 1 profile have an overall dismal outcome when referred for durable mechanical circulatory support and/or heart transplantation.  In this context, several centers have provided major contributions  to the role of temporary mechanical circulatory support as rescue therapy and as a bridge to decision in patients presenting in critical cardiogenic shock, but most have been anecdotal. The clinical and hemodynamic profiles associated with the selection of the various available options for temporary bridging warrants further discussion supported by a combination of available literature and a review from experienced front-line clinicians providing therapy for this particular subset of patients.  This session will first discuss the different types and outcomes of patients presenting in INTERMACs Profile 1, then will review the options available for the patient in shock - counterpulsation, percutaneous MCS, ECMO, Centrimag and Impella. This will be followed by a discussion of the subsequent steps. The different hemodynamic profiles each has to offer, the data presently available and the future technologies and relevant studies will be discussed.

Speaker(s):

PRE-MEETING SYMPOSIUM 02: Heart Allocation Policies: The Times They Are A-Changin' -- Experience with U.S. Policy for Heart Allocation

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY02a

Organ allocation remains a challenging issue, as there continues to be a shortage of available organs to meet the needs of those on transplant waiting lists. Organ allocation algorithms and listing priorities continue to be re-evaluated and adjusted in an effort to use this scarce resource fairly. This session will provide a forum to discuss this critical issue.

Speaker(s):
  • Joseph Rogers, MD, Duke University Medical Center, Durham, NC, United States

PRE-MEETING SYMPOSIUM 04: Bloody Virus: HIV, Hepatitis B and C -- What Transplant Professionals Need to Know About HIV Disease

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY04a

Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team.  This includes knowledge of drug interactions and the concerns for the various types of  immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use.  Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplants candidates with HIV, hepatitis B or C, before and after transplant.

Speaker(s):
  • Paolo A. Grossi, MD, PhD, Professor of Infectious Diseases, University of Insubria, Varese, Italy

PRE-MEETING SYMPOSIUM 06: Psychosocial Assessment: Tools, Tips and Opportunities -- Soft Factors, Hard Outcomes: Psychosocial Predictors of Post-transplant Success

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY06a

This session will review a range of tools available for teams to use to assist with the difficult process of psychosocial evaluation.  Seven experts in the area of psychosocial assessment and psychological distress will present the available tools with supporting evidence, as well as provide an opportunity to discuss and explore future opportunities for research.

Speaker(s):

PRE-MEETING SYMPOSIUM 05: Allograft Vasculopathy - A Challenge for All Ages -- Cardiac Allograft Vasculopathy, the Unsolved Problem: Registry Experience and Clinical Correlations

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY05a

Cardiac Allograft Vasculopathy limits intermediate and late survival in children, as well as adult transplant recipients, and affects even infant transplants. This symposium will address mechanisms and pathophysiology, as well as newer diagnostic tools and treatment agents, including basic science talks on potential targets for therapy. Our goal is to have pediatric and adult cardiologists share their experiences, and perhaps forge new collaborations to study this most challenging problem. We will invite experts in CAV from both Pediatric and Adult transplant community to speak of their experience with these patients, as well as start with basic science background.  The ending 15 minute panel discussion will have opinions from the group on an ideal research proposal to study this complex problem in the future. Attendees can ask questions regarding optimal immunosuppression for 2015, help design the ideal randomized clinical trial for all ages, and determine what endpoints and tools should be used for study.

Speaker(s):
  • Steven Kindel, MD, Children's Hospital of Wisconsin Milwaukee, WI, USA

PRE-MEETING SYMPOSIUM 03: Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management -- Pulmonary AMR: Recent Debates on Definitions and Diagnosis

Apr 15, 2015 8:30am ‐ Apr 15, 2015 8:45am

Identification: PMSY03a

Antibodies are associated with graft dysfunction but there is little reliable information in the literature to define this process. The ISHLT Pulmonary AMR working group is a multi-disciplinary group made up of clinicians, HLA experts and pathologists who have met to create a set of criteria and a standard working definition of pulmonary AMR.  The group will discuss the results of the international survey, diagnosis, and working definition of pulmonary AMR. A review HLA versus non-HLA antibodies and the role of complement pathways will be undertaken. The interplay of the innate and the adaptive immune system in AMR will be discussed. The session will provide a comprehensive review of management strategies. Cases will be used to discuss HLA issues and the management of pulmonary AMR.

Speaker(s):

PRE-MEETING SYMPOSIUM 02: Heart Allocation Policies: The Times They Are A-Changin' -- Experience with European Policy for Heart Allocation

Apr 15, 2015 8:45am ‐ Apr 15, 2015 9:00am

Identification: PMSY02b

Organ allocation remains a challenging issue, as there continues to be a shortage of available organs to meet the needs of those on transplant waiting lists. Organ allocation algorithms and listing priorities continue to be re-evaluated and adjusted in an effort to use this scarce resource fairly. This session will provide a forum to discuss this critical issue.

Speaker(s):

PRE-MEETING SYMPOSIUM 04: Bloody Virus: HIV, Hepatitis B and C -- Balancing Immunosuppression Medications and HIV: Don't Try This at Home

Apr 15, 2015 8:45am ‐ Apr 15, 2015 9:00am

Identification: PMSY04b

Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team.  This includes knowledge of drug interactions and the concerns for the various types of  immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use.  Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplants candidates with HIV, hepatitis B or C, before and after transplant.

Speaker(s):

PRE-MEETING SYMPOSIUM 06: Psychosocial Assessment: Tools, Tips and Opportunities -- The Psychosocial Assessment of Adult Organ Transplant Candidates: A Comprehensive Approach

Apr 15, 2015 8:45am ‐ Apr 15, 2015 9:00am

Identification: PMSY06b

This session will review a range of tools available for teams to use to assist with the difficult process of psychosocial evaluation.  Seven experts in the area of psychosocial assessment and psychological distress will present the available tools with supporting evidence, as well as provide an opportunity to discuss and explore future opportunities for research.

Speaker(s):
  • Quincy Young, PhD, RPsych, St. Paul's Hospital Vancouver, BC, CANADA

PRE-MEETING SYMPOSIUM 05: Allograft Vasculopathy - A Challenge for All Ages -- Endothelial Dysfunction and Cardiac Allograft Vasculopathy: New Assessment Tools for Patient Risk Stratification?

Apr 15, 2015 8:45am ‐ Apr 15, 2015 9:00am

Identification: PMSY05b

Cardiac Allograft Vasculopathy limits intermediate and late survival in children, as well as adult transplant recipients, and affects even infant transplants. This symposium will address mechanisms and pathophysiology, as well as newer diagnostic tools and treatment agents, including basic science talks on potential targets for therapy. Our goal is to have pediatric and adult cardiologists share their experiences, and perhaps forge new collaborations to study this most challenging problem. We will invite experts in CAV from both Pediatric and Adult transplant community to speak of their experience with these patients, as well as start with basic science background.  The ending 15 minute panel discussion will have opinions from the group on an ideal research proposal to study this complex problem in the future. Attendees can ask questions regarding optimal immunosuppression for 2015, help design the ideal randomized clinical trial for all ages, and determine what endpoints and tools should be used for study.

Speaker(s):
  • Monica M. Colvin, MD, University of Michigan Health System, Ann Arbor, MI, USA
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content